---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-007003"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:29:51.970096+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Anika Q3 revenue down 6% to $27.8M; files final Hyalofast PMA with mixed Phase III data

## Summary
- Q3 continuing ops rev $27.8M (-6% YoY); loss per share ($0.22); adj EPS $0.04; adj EBITDA $0.9M.
- Commercial Channel rev up 22% YoY; Integrity procedures on track to double in 2025; J&J extends Monovisc license to 2031.
- Commencing $15M share repurchase via 10b5-1 plan expected to complete by June 2026.
- Filed final Hyalofast PMA module; Phase III trial missed primary endpoints but showed significant secondary endpoint benefits.
- Hyalofast used in >35K patients globally; Breakthrough Device Designation; post-hoc analyses showed statistical significance in KOOS Pain.

## SEC filing metadata
- accession: 0001171843-25-007003
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184325007003/0001171843-25-007003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184325007003/f8k_110525.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-007003
- JSON: https://secwatch.observer/filing/0001171843-25-007003.json
- Plain text: https://secwatch.observer/filing/0001171843-25-007003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.